/ Print /

Managed healthcare executive Nav

Pharmacy Strategy

Seven barriers to prescribing PCSK9 inhibitors
June 22, 2017By Tracey Walker
The National Lipid Association releases interesting survey results on PCSK9 inhibitors prescription approval process.
Managed Care Pharmacy Survey 2017
June 21, 2017By Karen Appold
To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive conducted its annual pharmacy survey during the first quarter of 2017.
Top 10 states with the worst drug problems
June 14, 2017By Tracey Walker
WalletHub released a study comparing 50 states and the District in terms of 15 key metrics, ranging from arrest and overdose rates to opioid prescriptions and meth-lab incidents per capita.
Two strategies to help consumers lower drug costs
June 13, 2017By Scott Schnuckle
HealthPartners aims to improve price information for consumers. Here’s how.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watch
June 12, 2017By Erin Bastick PharmD RPh
Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Top four approaches to reduce pharmaceutical costs
Top four approaches to reduce pharmaceutical costs
June 11, 2017By Karen Appold
MCOs are fighting back against rising pharmaceutical costs. Here are the top strategies they are embracing.
Four health systems develop opioid mitigation programs
June 10, 2017By Mari Edlin
Alternatives to opioids programs emerge as viable tools to mitigate the crisis.
Four ways PBMs must change to thrive in the future
Four ways PBMs must change to thrive in the future
June 06, 2017By David Calabrese RPh MHP
The days of the traditional, channel-focused and largely enshrouded PBM business model have come and gone. Here’s what’s next.
Three ways technology is improving pharmacy
June 05, 2017By Donna Marbury
Technology advances in pharmacy include innovations that improve medication safety, efficiency, and patient compliance.
Value-based drug contracting shifts risk to manufacturers
June 03, 2017By Mari Edlin
Value-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.